What Is Changing in Medicare Part D for 2027 — and What Is Not
A source-backed explanation of the 2027 drug benefit, the end of the temporary standalone-PDP premium stabilization demonstration, the new $2,400 out-of-pocket threshold, the $700 standard deductible, Extra Help, negotiated drug prices, insulin, vaccines, the Medicare Prescription Payment Plan, and what beneficiaries should watch during Annual Enrollment.
Important: final 2027 plan premiums are not yet public
CMS has announced the 2027 national base beneficiary premium and the end of the temporary Part D Premium Stabilization Demonstration, but final plan-by-plan 2027 premiums, formularies, pharmacy networks and the full MA/Part D landscape are expected in mid-to-late September 2026. Any website or social post claiming to know every beneficiary's exact 2027 premium today is getting ahead of the official release.
Quick fact-check of the “Medicare Part D is ending” rumor
Medicare Part D is not ending. The federal benefit continues in 2027. Extra Help/LIS is not ending. The Inflation Reduction Act's annual out-of-pocket protection continues. What ends after December 31, 2026 is a temporary, voluntary CMS premium stabilization demonstration for participating standalone Part D plans (PDPs).
One wording correction: it is more accurate to say the IRA out-of-pocket cap protection remains — not that the dollar cap “stays at $2,000.” The statutory threshold is indexed after 2025: it was $2,000 in 2025, is $2,100 in 2026, and will be $2,400 in 2027.
1. Executive summary: the 2027 Part D changes in plain English
The biggest 2027 story is not that Medicare drug coverage disappears. It is that the redesigned Part D benefit continues while one temporary premium-control demonstration for standalone PDPs ends.
What changes
- The annual Part D out-of-pocket threshold rises from $2,100 in 2026 to $2,400 in 2027.
- The defined standard deductible rises from $615 to $700. A plan may charge less or no deductible.
- The temporary Part D Premium Stabilization Demonstration for standalone PDPs ends after 2026.
- The national base beneficiary premium rises from $38.99 to $41.33.
- The Part D national average monthly bid amount rises from $239.27 to $296.05.
- Negotiated maximum fair prices for 15 additional high-spend Part D drugs take effect January 1, 2027.
What does not end
- Medicare Part D coverage.
- Extra Help / Low-Income Subsidy (LIS).
- $0 beneficiary cost sharing after reaching the annual Part D OOP threshold for covered Part D drugs.
- The three-phase redesigned Part D benefit: deductible, initial coverage, catastrophic.
- No coverage-gap / “donut hole” phase.
- Medicare Prescription Payment Plan availability from all Part D sponsors.
- IRA protections for covered insulin and ACIP-recommended adult vaccines.
- The Manufacturer Discount Program that replaced the old Coverage Gap Discount Program.
2. 2026 vs. 2027: side-by-side comparison
| Part D item | 2026 | 2027 | What it means |
|---|---|---|---|
| Defined standard deductible | $615 | $700 | Higher by $85 |
| Annual OOP threshold / catastrophic trigger | $2,100 | $2,400 | Higher by $300; then $0 cost sharing for covered Part D drugs |
| Beneficiary cost sharing in catastrophic phase | $0 | $0 | No change |
| Coverage gap / donut hole | Eliminated | Eliminated | Does not return |
| Premium Stabilization Demonstration for PDPs | $10 uniform premium reduction; participating plans subject to $50 year-over-year premium increase limit | Ends | PDP pricing returns to regular market conditions |
| National base beneficiary premium | $38.99 | $41.33 | 6% statutory increase cap applies to this base amount |
| National average monthly bid amount (NAMBA) | $239.27 | $296.05 | Technical bidding benchmark, not the premium every enrollee pays |
| Final plan-specific premiums | Published | Not yet finalized as of Aug. 6, 2026 | CMS expects full landscape in mid-to-late September 2026 |
| Extra Help / LIS | Continues | Continues | Not terminated by the demonstration's end |
| Medicare Prescription Payment Plan | Required | Required | Spreads OOP drug costs across monthly bills; does not reduce total cost |
| Negotiated Medicare drug prices | First 10 selected drugs effective | 15 more selected Part D drugs effective | 25 negotiated drugs total across the first two cycles, assuming continued program participation |
4. The 2027 out-of-pocket threshold is $2,400 — not $2,000
The IRA established a much lower annual Part D out-of-pocket threshold beginning in 2025 and requires the amount to be indexed in later years. That is why the dollar amount changes even though the protection itself continues.
$2,000
Initial statutory amount under the redesigned benefit.
$2,100
Indexed annual OOP threshold.
$2,400
CMS finalized the indexed threshold using the statutory annual percentage increase methodology.
The 2027 Rate Announcement reports a 13.65% annual percentage increase for updating the relevant Part D standard-benefit parameters. The $2,100 threshold is multiplied by the update and rounded to the nearest $50, producing $2,400.
What happens after the beneficiary reaches $2,400?
For the remainder of that calendar year, the beneficiary enters catastrophic coverage and owes $0 cost sharing for covered Part D drugs. Monthly plan premiums are separate and do not count toward the Part D out-of-pocket threshold.
5. The defined standard deductible rises to $700 in 2027
CMS finalized a $700 defined standard Part D deductible for 2027, up from $615 in 2026. This is the maximum deductible under the defined standard benefit structure. Individual plans may offer a lower deductible, no deductible, or may exempt certain tiers from the deductible depending on their approved benefit design.
Do not confuse the deductible with the $2,400 annual OOP threshold
The deductible is the early-year amount a beneficiary may have to satisfy before the plan's initial coverage cost-sharing rules apply. The $2,400 threshold is the annual TrOOP level that triggers catastrophic coverage and $0 beneficiary cost sharing for covered Part D drugs.
6. How the redesigned Part D benefit works in 2027
The redesigned benefit has three phases. The old coverage gap (“donut hole”) does not come back in 2027.
Deductible
Under the defined standard design, the enrollee generally pays 100% of covered drug costs until the deductible is satisfied, up to the $700 standard deductible. Plans may offer richer designs.
Initial coverage
Under the defined standard benefit, enrollee cost sharing is generally 25% for covered Part D drugs until TrOOP reaches $2,400. Plan designs can use actuarially equivalent copays/coinsurance.
Catastrophic
After the $2,400 annual OOP threshold is reached, the enrollee owes $0 cost sharing for covered Part D drugs for the rest of the calendar year.
Who pays behind the scenes?
The IRA changed how liability is divided among the Part D sponsor, drug manufacturer and Medicare. In the catastrophic phase, the enrollee's share remains zero, while plans, manufacturers and CMS divide the remaining liability under statutory rules. For selected drugs subject to negotiated prices, CMS also uses a Selected Drug Subsidy structure in place of certain manufacturer-discount treatment.
8. Extra Help / Low-Income Subsidy (LIS) continues in 2027
There is no CMS announcement ending Extra Help. The Low-Income Subsidy remains part of Medicare Part D and continues to help eligible beneficiaries with premiums, deductibles and prescription cost sharing.
Who can be automatically eligible?
- People with full Medicaid benefits.
- People receiving Supplemental Security Income (SSI).
- People enrolled in qualifying Medicare Savings Programs such as QMB, SLMB or QI.
Other beneficiaries can apply for Extra Help if they meet applicable income and resource rules.
2027 LIS cost-sharing parameters
CMS's 2027 Rate Announcement shows continued $0 deductibles for full-subsidy beneficiaries and updated maximum copayments. For beneficiaries in the full-subsidy category between 100% and 150% of the federal poverty level, the maximum copays shown for 2027 are $5.80 for generic/preferred multi-source drugs and $14.40 for other drugs before reaching the OOP threshold. Other full-benefit dual categories have lower maximum copays, and certain institutionalized or qualifying home/community-based beneficiaries have $0 copays.
Income/resource eligibility amounts and cost-sharing categories vary by status and are updated separately. Beneficiaries should verify current qualification rules through Medicare or Social Security rather than relying on a prior-year dollar threshold.
9. Medicare negotiated drug prices: 15 additional Part D drugs take effect in 2027
CMS negotiated maximum fair prices (MFPs) for 15 high-spend Part D drugs for the second negotiation cycle. These prices become effective January 1, 2027. CMS estimates that, under the defined standard benefit, beneficiaries would save approximately $685 million in out-of-pocket costs when the 2027 prices are in effect, based on its analysis.
| Selected drug(s) | Common use | 2027 negotiated 30-day price* | 2024 list price* | Discount vs. 2024 list |
|---|---|---|---|---|
| Ozempic / Rybelsus / Wegovy | Diabetes; cardiovascular disease; obesity/overweight indications | $274 | $959 | 71% |
| Trelegy Ellipta | Asthma; COPD | $175 | $654 | 73% |
| Xtandi | Prostate cancer | $7,004 | $13,480 | 48% |
| Pomalyst | Multiple myeloma; Kaposi sarcoma | $8,650 | $21,744 | 60% |
| Ofev | Idiopathic pulmonary fibrosis | $6,350 | $12,622 | 50% |
| Ibrance | Breast cancer | $7,871 | $15,741 | 50% |
| Linzess | Chronic idiopathic constipation; IBS-C | $136 | $539 | 75% |
| Calquence | CLL/SLL; mantle cell lymphoma | $8,600 | $14,228 | 40% |
| Austedo / Austedo XR | Huntington's chorea; tardive dyskinesia | $4,093 | $6,623 | 38% |
| Breo Ellipta | Asthma; COPD | $67 | $397 | 83% |
| Xifaxan | Hepatic encephalopathy; IBS-D | $1,000 | $2,696 | 63% |
| Vraylar | Bipolar I; major depression adjunct; schizophrenia | $770 | $1,376 | 44% |
| Tradjenta | Type 2 diabetes | $78 | $488 | 84% |
| Janumet / Janumet XR | Type 2 diabetes | $80 | $526 | 85% |
| Otezla / Otezla XR | Behçet's oral ulcers; plaque psoriasis; psoriatic arthritis | $1,650 | $4,722 | 65% |
*CMS's table uses a 30-day-equivalent negotiated price and 2024 Wholesale Acquisition Cost-based list price. Actual beneficiary cost sharing is determined by Part D benefit rules and plan design; the negotiated price is not necessarily the amount a beneficiary pays at the pharmacy.
Formulary protection for selected drugs
CMS states that Medicare prescription drug plans — both standalone PDPs and MA-PDs — must include selected drugs with agreed negotiated prices on their formularies, subject to CMS's formulary review and applicable statutory/regulatory rules.
10. Insulin and adult vaccine protections continue
Covered insulin
The IRA's special cost-sharing protection for covered insulin continues. Beginning in 2026, the monthly cost-sharing cap for a covered insulin product is the lesser of $35, 25% of the applicable negotiated maximum fair price when relevant, or 25% of the plan's negotiated price, subject to statutory rules.
ACIP-recommended adult vaccines
Part D continues to cover qualifying adult vaccines recommended by the Advisory Committee on Immunization Practices with $0 beneficiary cost sharing when covered under Part D.
11. Medicare Prescription Payment Plan continues in 2027
All Medicare Part D plans are required to offer the Medicare Prescription Payment Plan. It lets an enrollee spread covered out-of-pocket Part D drug costs into monthly plan bills rather than paying the entire amount at the pharmacy counter.
What it can do
- Improve cash flow for people with large early-year prescription costs.
- Replace a large point-of-sale payment with capped monthly billing.
- Continue to work alongside the annual Part D OOP protection.
What it does not do
- It does not lower the total amount owed.
- It is not a premium subsidy.
- It does not make non-covered drugs count toward TrOOP.
- It is separate from Extra Help.
12. TrOOP: what counts toward the annual Part D out-of-pocket threshold?
TrOOP (true out-of-pocket costs) is the Medicare accounting measure that determines when an enrollee reaches the annual Part D OOP threshold and enters catastrophic coverage. Not every dollar connected to prescriptions counts.
Examples that can count
- The beneficiary's deductible, copayments and coinsurance for covered Part D drugs.
- Amounts paid on the beneficiary's behalf by qualifying third parties.
- Certain supplemental Part D benefits and EGWP supplemental coverage included under the IRA's revised TrOOP rules.
- Extra Help payments that Medicare rules treat as incurred costs for purposes of the threshold.
Examples that generally do not count
- Monthly Part D plan premiums.
- Drugs that are not covered under Part D or that are excluded from the plan's coverage and not obtained through an approved exception.
- Over-the-counter drugs.
- Payments made under arrangements that Medicare rules exclude from TrOOP.
- The $50 GLP-1 Bridge copay, because the Bridge operates outside the Part D benefit flow.
13. Standalone PDP vs. Medicare Advantage drug coverage: who is most directly affected by the demonstration ending?
Standalone PDP enrollees
The discontinued demonstration was specifically designed for standalone Part D plans. These plans are therefore the group most directly tied to the loss of the demonstration's temporary premium reduction and special year-over-year premium increase limit.
That does not mean every standalone PDP premium will rise by the same amount. Plan-specific 2027 rates are still pending.
MA-PD enrollees
Medicare Advantage plans with drug coverage were not the primary target of this standalone-PDP premium demonstration. MA organizations can use MA rebate dollars in ways that affect the drug-premium component, so MA-PD premium dynamics can differ substantially from standalone PDPs.
The core Part D benefit protections — including the $2,400 OOP threshold and $0 catastrophic cost sharing — apply within Part D regardless of whether drug coverage is standalone or built into MA, subject to plan design and LIS status.
KFF reported that in 2026 the enrollment-weighted average monthly PDP premium was about $36 versus about $8 for the drug-coverage component in MA-PDs, illustrating why premium comparisons alone can look very different across the two markets. Beneficiaries should also compare provider networks, medical benefits, drug formularies and total annual costs before switching coverage types.
14. Separate 2026–2027 update: the Medicare GLP-1 Bridge
CMS launched a separate Medicare GLP-1 Bridge that operates from July 1, 2026 through December 31, 2027 for eligible Part D beneficiaries and certain eligible GLP-1 drugs. The Bridge operates outside the normal Part D benefit payment flow.
Key Bridge rules
- Eligible beneficiaries have a $50 copay for qualifying Bridge drugs.
- The regular Part D deductible does not apply to Bridge claims.
- The $50 Bridge copay does not count toward Part D TrOOP.
- There is no LIS subsidy applied to the Bridge copay.
Why this belongs in a 2027 guide
The Bridge continues throughout 2027 and intersects with some of the same drug classes that are receiving significant Medicare policy attention. It should not be confused with standard Part D coverage, the Medicare Prescription Payment Plan, or the PDP Premium Stabilization Demonstration.
15. What beneficiaries should do before 2027 Annual Enrollment
Because final plan-specific 2027 details will be released later in 2026, the most important action is to compare the beneficiary's actual drugs, pharmacies and total costs — not just the premium.
1. Review the ANOC
Read the plan's Annual Notice of Change carefully for premium, deductible, formulary, tier, pharmacy and utilization-management changes.
2. Re-run every drug
Check each medication, strength, quantity and frequency against the 2027 formulary and preferred pharmacy network.
3. Compare total annual cost
A lower premium can still be more expensive overall if drug copays, coinsurance or pharmacy pricing are worse.
4. Check Extra Help
Beneficiaries with limited income/resources should confirm whether they qualify for LIS or a Medicare Savings Program.
5. Consider cash-flow needs
For high prescription costs early in the year, ask whether the Medicare Prescription Payment Plan is useful.
6. Do not switch based on a rumor
Wait for finalized 2027 plan data and compare the full medical and drug picture before changing plans.
16. Agent talking points: how to explain this accurately
Recommended 30-second explanation
“Medicare Part D is not ending. What ends after 2026 is a temporary CMS program that helped stabilize premiums for participating standalone drug plans. The Part D benefit continues, Extra Help continues, and the annual out-of-pocket protection continues. For 2027, the standard deductible is $700 and the annual Part D out-of-pocket threshold is $2,400, after which covered Part D drugs have $0 beneficiary cost sharing for the rest of the year. We will need to review each person's 2027 plan because final premiums and formularies are not released until later in the year.”
Compliance-safe wording to use
Wording to avoid
- “The $2,000 cap stays the same.” Incorrect: the protection stays, but the threshold is $2,400 in 2027.
- “All Part D premiums will increase by ___.” Not supportable yet: plan-specific premiums are not final.
- “The government is ending Part D subsidies.” Overbroad: a specific temporary standalone-PDP demonstration ends; normal Part D financing and LIS continue.
- “Medicare Advantage is automatically cheaper.” Premiums alone do not establish total cost or suitability.
17. Myths vs. facts
18. Detailed Medicare Part D 2027 FAQ
Is Medicare Part D being eliminated in 2027?
No. Medicare Part D remains in effect. CMS's July 28, 2026 announcement concerns the end of the temporary Part D Premium Stabilization Demonstration for standalone PDPs.
What is the Part D out-of-pocket limit in 2027?
The 2027 annual out-of-pocket threshold is $2,400. After an enrollee reaches the threshold through qualifying TrOOP costs, the enrollee owes $0 cost sharing for covered Part D drugs for the rest of that calendar year.
Why did the cap go from $2,000 to $2,100 and then $2,400?
The IRA set the 2025 threshold at $2,000 and requires later-year thresholds to be indexed using a statutory annual percentage increase. CMS finalized $2,100 for 2026 and $2,400 for 2027.
Does the $2,400 include my monthly plan premium?
No. Part D premiums do not count toward the annual TrOOP threshold.
What is the 2027 Part D deductible?
The defined standard deductible is $700. Plans may design lower deductibles or no deductible, subject to CMS rules.
Is the donut hole coming back?
No. The redesigned Part D structure has deductible, initial coverage and catastrophic phases; the old coverage-gap phase was eliminated beginning in 2025.
What exactly was the Premium Stabilization Demonstration?
It was a voluntary CMS demonstration for standalone PDPs created to reduce premium volatility during implementation of the redesigned Part D benefit. In 2025 it included a $15 uniform premium reduction and $35 year-over-year premium increase limit; in 2026, a $10 reduction and $50 increase limit. CMS will discontinue it after 2026.
Will my 2027 standalone Part D premium increase?
Possibly, but the amount cannot be determined from the CMS demonstration announcement alone. Actual premiums will vary by plan and region. Final 2027 plan information is expected in mid-to-late September 2026.
What is the $41.33 number for 2027?
It is the 2027 national base beneficiary premium, an input into the formula used to determine plan-specific basic premiums. It is not the premium that every Part D enrollee pays.
What is the $296.05 number?
That is the 2027 national average monthly bid amount (NAMBA), an enrollment-weighted average of applicable Part D plan bids used in calculating federal plan subsidies. It is not a consumer premium.
Does Extra Help end when the demonstration ends?
No. Extra Help/LIS is a separate Medicare program and continues.
Will full Extra Help beneficiaries have a deductible in 2027?
CMS's 2027 parameters continue a $0 deductible for full-subsidy LIS beneficiaries, subject to the person's LIS category and Medicare rules.
Are insulin protections ending?
No. The IRA's covered-insulin cost-sharing protection continues. Beginning in 2026 the cap is generally the lesser of $35, 25% of the maximum fair price when applicable, or 25% of the plan negotiated price.
Are covered adult vaccines still $0?
Yes, qualifying ACIP-recommended adult vaccines covered under Part D continue with $0 beneficiary cost sharing.
Does the Medicare Prescription Payment Plan continue in 2027?
Yes. All Part D sponsors must continue offering it. It spreads out out-of-pocket costs but does not reduce the total amount owed.
What are the new 2027 negotiated drugs?
CMS's second negotiation cycle covers 15 selected Part D drugs/drug groupings, including Ozempic/Rybelsus/Wegovy, Trelegy Ellipta, Xtandi, Pomalyst, Ofev, Ibrance, Linzess, Calquence, Austedo/Austedo XR, Breo Ellipta, Xifaxan, Vraylar, Tradjenta, Janumet/Janumet XR and Otezla/Otezla XR.
Does a negotiated price mean I pay that exact amount?
No. The MFP is a Medicare-negotiated price available through the statutory program. Beneficiary cost sharing is governed by Part D benefit rules, plan design, the drug's coverage status, LIS status and the stage of the benefit.
What happens if my drug is not on the 2027 formulary?
Beneficiaries should review the plan's formulary and applicable transition/exception rights. A drug that is not covered generally does not count toward TrOOP unless it becomes covered through the plan's coverage-determination/exception process.
Should I switch from a standalone PDP to Medicare Advantage because the demonstration ends?
Not based on this change alone. Compare total annual prescription costs, provider networks, hospitals, medical copays, maximum medical out-of-pocket exposure, drug coverage, pharmacies and personal preferences before changing coverage types.
When can I see final 2027 plans?
CMS says the full 2027 Medicare Advantage and Part D landscape and final average premiums will be released in mid-to-late September 2026, ahead of Annual Enrollment.
19. Key Part D dates to know
20. Primary sources and further reading
For a topic this important, the best practice is to rely first on CMS and Medicare.gov, then use independent analysis for context. The links below are the sources used to build this page.
2027 data watch
This page should be refreshed when CMS publishes the final 2027 MA/Part D landscape in September 2026. At that point, add national and state-level plan counts, final average premiums, specific PDP premium examples, benchmark/LIS plan data, and any final formulary or market-exit information.